Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01172938 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 504
- Enrollment target
NCT01172938 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 504 participants.
The verdict
NCT01172938, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 504 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.
Interventions
- DRUG Apremilast 30mg
- DRUG Apremilast 20mg
- DRUG Placebo + 20 mg Apremilast
- DRUG Placebo + 30 mg Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 504 participants |
| Start Date | 2010-06-02 |
| Est. Completion | 2016-10-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01172938
The ClinicalTrials.gov registry entry for NCT01172938 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Apremilast 30mg is the first listed.
NCT01172938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01172938 about?
NCT01172938 is a clinical study titled "Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis". The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.
What is the current status of trial NCT01172938?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 504 participants. The study started on 2010-06-02. Estimated completion is 2016-10-27.
What interventions are being tested in trial NCT01172938?
The interventions under investigation include: Apremilast 30mg (DRUG), Apremilast 20mg (DRUG), Placebo + 20 mg Apremilast (DRUG), Placebo + 30 mg Apremilast (DRUG).
Who is sponsoring clinical trial NCT01172938?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.